Artificial Intelligence and Big Data

DR. REGENOLD GMBH HAS SET ITSELF THE GOAL OF SIMPLIFYING THE TRADITIONAL PROCESS OF DECISION MAKING BY RESEARCHERS AND PHYSICIANS USING ARTIFICIAL INTELLIGENCE, THUS MAKING DRUG DEVELOPMENT FASTER AND CHEAPER.

- DR. JÜRGEN REGENOLD, Managing Director

Artificial Intelligence and Big Data

We aim to help organisations move to continuous decision making in their development, regulatory and pharmacovigilance processes by generating insights from structured and unstructured data using algorithms, machine learning and artificial intelligence. Real world data (RWD) and real world evidence (RWE) are playing an increasing role in health care decisions. The 21st Century Cures Act, passed in 2016, modified the FDA drug approval process which now places additional focus on the use of these types of data to support regulatory decision making.

The Regenold AI/Analytics team is able to bridge the gap between domain experts and the SAS platform to develop tailored solutions for our clients. This is possible due to our close collaborative partnership with SAS and the use of their software tools.

We are experts at performing analytics on text data and provide services in:

  • Literature Screening
  • Text mining for report automation

Our current focus is on the processes within development, regulatory and pharmacovigilance helping clients identify opportunities, developing solutions and business benefits.



Have a question concerning AI and Big Data? Contact Soundarya Palanisamy.